BHC:CA:TSX-Bausch Health Companies Inc.

EQUITY | Drug Manufacturers | Toronto Stock Exchange

Last Closing

CAD 32.37

Change

-1.24 (-3.69)%

Market Cap

CAD 11.32B

Volume

1.14M

Analyst Target

CAD 21.57
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-10-17 )

Largest Industry Peers for Drug Manufacturers

ETFs Containing BHC:CA

QHY:CA Mackenzie US High Yield B.. 0.98 % 0.56 %

N/A

CAD 0.04B
NHYB:CA NBI High Yield Bond ETF 0.89 % 0.00 %

+0.07 (+0.34%)

CAD 1.07B
CJNK 0.00 % 0.30 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A F
Dividend Return N/A N/A N/A N/A F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A F
Risk Adjusted Return N/A N/A N/A N/A F
Market Capitalization 11.32B 86% B+ 98% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers) Ratio vs. Market (Toronto Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -4.80 46% 79%
Price/Book Ratio 1.93 83% 27%
Price / Cash Flow Ratio 1.24 31% 47%
Price/Free Cash Flow Ratio 6.07 15% 39%
Management Effectiveness  
Return on Equity -39.04% 23% 8%
Return on Invested Capital 0.86% 85% 27%
Return on Assets -5.03% 46% 19%
Debt to Equity Ratio 559.75% 11% 3%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.